How Has the Alpha Emitter Market Evolved Historically and What is its Current Size?
The alpha emitter market has seen considerable growth due to a variety of factors.
• The size of the alpha emitter market has been soaring in the past years. The projections depict a growth from $1.3 billion in 2024 to $1.61 billion in 2025, showing a Compound Annual Growth Rate (CAGR) of 23.7%.
The robust growth during the historic period can be credited to the growing incidences of cancer, enhanced research investments, government aid and financing, the rise in the aging population, and the development of radiotherapy centers.
What Is The Projected Growth Of The Alpha Emitter Market Size In The Coming Years?
The alpha emitter market is expected to maintain its strong growth trajectory in upcoming years.
• The market for alpha emitters is predicted to experience a significant spike in the coming years, reaching a value of $3.73 billion in 2029 with an estimated compound annual growth rate (CAGR) of 23.4%.
This upward trajectory during the projected period is due to factors such as increasing health care spending, higher incidence rates of heart conditions, more usage of combined therapies, a growing trend towards targeted alpha therapy, and an upsurge in research and development initiatives. Key trends in the forecast period consist of progress in imaging technologies, innovative products, strategic alliances, advancements in the development of radiopharmaceuticals, and the creation of new alpha-emitting isotopes.
What Are the Critical Driver Fuelling The Alpha Emitter Market's Growth?
The surge in cancer occurrence is anticipated to boost the alpha emitter market's growth. Characterized by unregulated growth and dispersion of abnormal cells that potentially form tumors and invade nearby tissues, cancer is increasingly prevalent. This surge is linked to various factors, including aging demographics, environmental exposure, lifestyle alterations, and enhanced diagnosis methods. Alpha emitters, employed to accurately target and eliminate cancer cells, sparing the surrounding healthy tissues, are instrumental in treating cancer. For example, data from the Australian Institute of Health and Welfare, a government health administration in Australia, predicts that the count of Americans diagnosed with cancer, excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin, will rise from 151,000 individuals in 2021 to 185,000 by 2030. Hence, the accelerating incidence of cancer is fueling the alpha emitter market's expansion.
What Are The Principal Market Segments In The Global Alpha Emitter Industry?
The alpha emittermarket covered in this report is segmented –
1) By Type Of Radionuclide: Radium, Actinium, Lead, Bismuth, Other Types Of Radionuclides
2) By Source: Natural Sources, Artificially Produced Sources, Other Sources
3) By Application: Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Lymphoma, Melanoma, Bone Metastasis, Other Applications
4) By End-User: Hospitals, Medical Research Institutions, Other End-Users
Subsegments:
1) By Radium: Radium-223, Radium-226, Radium-228
2) By Actinium: Actinium-227, Actinium-225
3) By Lead: Lead-210, Lead-212
4) By Bismuth: Bismuth-213, Bismuth-212
5) By Other Types of Radionuclides: Thorium, Polonium, Francium
Pre-Book The Alpha Emitter Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Alpha Emitter Industry?
Leading organizations in the alpha-emitter market are shifting their focus towards introducing novel solutions, like alpha-radiating radionuclides produced through cyclotrons, to establish a competitive advantage. Alpha-emitting radionuclides, which are radioactive isotopes that emit alpha particles during decay, are created in a cyclotron by accelerating charged particles to extraordinary energies. Case in point, Ionetix, a cyclotron and technology firm based in the US, manufactured its first alpha-emitting radionuclide, called Astatine-211 (At-211), in April 2023 at their newly opened Alpha Isotope Manufacturing establishment in Lansing, Michigan. This is regarded as the first facility in the US that is specifically committed to the production of alpha-emitting radionuclides using cyclotron technology. The facility's production capabilities were made possible by activating a 30 MeV cyclotron, specifically made for accelerating alpha particles, thereby aiding the high-yield production of At-211 and Actinium-225 (Ac-225).
Who Are the Key Players In The Alpha Emitter Market?
Major companies operating in the alpha emitter market are:
• Cardinal Health Inc.
• Bayer AG
• Lantheus Holdings Inc.
• Curium Pharma
• Eckert & Ziegler BEBIG GmbH
• Telix Pharmaceuticals Limited
• NorthStar Medical Radioisotopes LLC
• ITM Isotope Technologies Munich SE
• Blue Earth Diagnostics Ltd.
• International Isotopes Inc.
• IBA Radiopharma Solutions
• Orano Med LLC
• ARTbio AS
• Actinium Pharmaceuticals Inc.
• Clarity Pharmaceuticals Ltd.
• RadioMedix Inc.
• Nordic Nanovector ASA
• Convergent Therapeutics
• TAE Life Sciences
• ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH
• Fusion Pharmaceuticals Inc.
What Are The Regional Insights Into The Alpha Emitter Market?
North America was the largest region in the alpha emitter market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha emitter market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
